Btubulinbased

Btubulinbased, also known as botulinum toxin BE- vector based, is a proprietary technology used for the targeted and controlled release of molecules, including small interfering RNA (siRNA) and other oligonucleotides. This technology is based on the use of mutated Btubulin proteins, which are the building blocks of microtubules, to create a platform for delivering therapeutic molecules to specific cells or tissues.

The Btubulinbased platform harnesses the cell's own microtubules to transport and release the therapeutic molecules. This approach aims to increase specificity and reduce off-target effects associated with systemic delivery methods. By targeting specific cells or tissues, Btubulinbased technology may offer enhanced therapeutic efficacy while minimizing side effects.

This platform involves the insertion of siRNA or other molecules into the Btubulin protein, which then bind to the microtubules in the targeted cells. Upon reaching the target site, such as cancer cells or neurons, the therapeutic molecules are released, allowing them to exert their effects. The delivery efficiency and specificity of Btubulinbased have been demonstrated through in vitro and in vivo studies, showing promise for various therapeutic applications.

Ongoing and future investigations aim to further understand the potential of Btubulinbased technology in various fields, including cancer treatment, neurodegenerative diseases, and other systemic conditions. While the early results are promising, further research is needed to establish the efficacy and safety of this platform as a therapeutic approach. As research continues, Btubulinbased technology holds potential for targeted and more effective treatments.